OR WAIT null SECS
© 2023 MJH Life Sciences™ and Formulary Watch. All rights reserved.
Recent FDA action (through October 2009) related to doxorubicin, trabectedin, carisbamate, alogliptin/pioglitazone, HPV vaccine, pralatrexate, romidepsin, hyaluronic acid, laromustine, clofarabine, prGCD, KNS-760704, rifaximin, hexvix, and quinazoline495
Complete response
Recommended for approval
Not recommended for approval
Priority review
Orphan drug designations